<DOC>
	<DOCNO>NCT00002240</DOCNO>
	<brief_summary>The purpose study evaluate new protease inhibitor know BMS-232632 . This drug give combination 2 anti-HIV drug ( stavudine didanosine ) . The effectiveness BMS-232632 HIV infection compare nelfinavir , protease inhibitor already commonly prescribe .</brief_summary>
	<brief_title>Study New Protease Inhibitor , BMS-232632 , Combination With Other Anti-HIV Drugs</brief_title>
	<detailed_description>Patients randomize receive one two drug regimen : BMS-232632 , ddI , d4T NFV , ddI , d4T . Three different dos BMS-232632 use study . Randomization stratify HIV RNA level ( le 30,000 copies/ml versus 30,000 great copies/ml ) . Patients remain drug regimen 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have HIV blood level 2,000 200,000 copies/ml . Have CD4 cell count least 100 cells/mm3 . Are 18 year age old . Are available followup least 48 week . Agree use barrier method birth control ( condom ) study . Exclusion Criteria Patients eligible study : Have ever receive antiHIV ( antiretroviral ) treatment . Have HIVrelated opportunistic infection condition time study entry . Have primary HIV infection , mean recently infect . Have severe diarrhea within 30 day study entry . Have hemophilia . Have history pancreatitis , hepatitis , peripheral neuropathy . Are unable tolerate oral medication . Are pregnant breastfeeding . Abuse alcohol drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>